App-Quantinova.ai

Balance rehabilitation for people with mild to moderate Parkinson’s disease: A scoping review of dual-task training interventions and outcome measures

N. Cakmak - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Building a Global Parkinson’s Genetics Program (GP2): Clinical Cohorts Integration Working Group

J. Joubert - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Challenges around end-of-life care for people with Parkinson’s disease in Kenya

N. Fothergill-Misbah - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Characterising the incidence of comorbidities, hospitalisations, and death in patients diagnosed with Huntington’s disease: A cohort study of linked Swedish National Registries (2002-2019)

H. Furby - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

Clinical Outcomes in Parkinson’s with COVID 19 during the’ first wave’ in West Berkshire, United Kingdom (UK)

M. Khwaja - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Parkinson's disease

N/A

Cognitive complaints, anxiety, depression and reporting of pain in Parkinson’s Disease in a multi-ethnic population: Dissimilarities between White and Non-White patients

K. Rukavina - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Correlating LRRK2 activation status in peripheral blood to urine BMPs in monogenic and idiopathic Parkinson’s disease

S. Gomes - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Velaglucerase alfa

Covid-19 associated Opsoclonus-Myoclonus Syndrome with encephalopathy

A. Tageldin - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Encephalopathy

N/A

DAT-IQ improves power to detect longitudinal change in DaT deficit in SURE-PD3

Z. Fan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Ioflupane

Deep learning based detection of Parkinson’s disease (PD) in Magnetic Resonance Imaging (MRI) brain scans

M. Courtman - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Developing 31-phosphorus magnetic resonance spectroscopy (31P-MRS) as an imaging biomarker to identify mitochondrial dysfunction in Parkinson’s disease

T. Payne - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Adenosine-5'-triphosphate

Development of the Huntington’s Disease Integrated Staging System (HD-ISS)

S. Tabrizi - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

Diagnostic accuracy in an incidence cohort of Parkinson’s disease

B. Brownlee - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Disease stage and nigrostriatal integrity predict motor progression in individuals with early Parkinson’s disease

H. Jackson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Dopamine hydrochloride

Disentangling prodromal from non-prodromal symptoms of Parkinson’s disease

H. Jackson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Dystonic tremor and ataxia as presenting symptoms of multiple sclerosis

S. Healy - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Botox

Early detection of change in motor and cognitive symptoms in a longitudinal Progressive Supranuclear Palsy cohort – the OxQUIP study.

M. Pereira - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Progressive supranuclear palsy

Levodopa

East Asian Parkinson’s Disease Genomics Consortium – An introduction

K. Mok - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study

N. Pavese - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Safinamide

Effects of Levodopa-Carbidopa Intestinal Gel on Dyskinesia and Non-Motor Symptoms including Sleep: Results from a Meta-Analysis with 24-month follow-up

K. Chaudhuri - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Carbidopa and Levodopa

Filters

45280 Abstracts